Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy

Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy

“…These anti-fibrotic effects were mediated via microRNA 29 induction (Kanasaki et al 2014, Shi et al 2015. Furthermore, gemigliptin normalized albuminuria, mesangial expansion, oxidative damage and podocyte apoptosis in the kidneys of db/db mice (Jung et al 2015, Moon et al 2016). …”

“…DPP-4 inhibitors were found to have renal beneficial effects in animal models of non-diabetic nephropathy such as 5/6 nephrectomy (Tsuprykov et al 2016) Streptozotocin-induced diabetic CD-1 mice Linagliptin -Reduced plasma cystatin C levels and UACR -Ameliorated kidney fibrosis, glomerular size and mesangial area Kanasaki et al (2014), Shi et al (2015) Diabetic db/db mice Gemigliptin -Suppressed albuminuria -Decreased mesangial expansion -Suppressed podocyte apoptosis -Reduced oxidative damage Jung et al (2015), Moon et al (2016) Glp1r 2-kidney-1-clip hypertension (Chaykovska et al 2013), tacrolimus-induced kidney injury (Lim et al 2015), rat Thy-1 glomerulonephritis model (Higashijima et al 2015) and unilateral ureteral obstruction (Min et al 2014).…”

DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury

“…These findings are in agreement with a recent study showing that the DPPIV inhibition prevents podocyte loss associated with the suppression of oxidative damage. 33 Taken together, these results suggest that activated DPPIV may induce podocyte dysfunction, such as podocyte loss, which is accompanied by increased albuminuria. Another interesting finding was that various DPPIV inhibitors could differentially affect DPPIV activity and nephrin restoration.…”

Incretin-based therapy: renal effects

“…У мышей db/db, получавших гемиглиптин (100 мг/кг/сутки в течение 12 недель), в сравнении с груп-пой плацебо наблюдались меньшие значения альбуми-нурии, ингибирование апоптоза подоцитов, уменьшение экспрессии рецепторов поздних продуктов гликирования и интегринзависимых киназ [65]. Нефропротективные свойства гемиглиптина продемонстрированы в модели по-чечного фиброза обструктивного генеза [66].…”